MIGUEL FONSECA-MORENO: Open Payments
NPI 1417724402 · ANTHEM, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$299 in 14 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $299
Food & beverage: $299
| Company | Payments | Amount |
|---|---|---|
| Almatica Pharma LLC | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Boston Scientific Corporation | 1 | $36 |
| Lundbeck LLC | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
Products named: REXULTI, TERIPARATIDE, General - Therapies, GEMTESA, BREZTRI, ZENPEP, Ozempic, KISUNLA.
Industry payments across AZ — which companies pay providers there.
